Dynavax Technologies Corporation Stock price

Equities

DVAX

US2681582019

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:26:35 2024-03-28 am EDT 5-day change 1st Jan Change
12.37 USD -0.32% Intraday chart for Dynavax Technologies Corporation +1.69% -11.55%
Sales 2024 * 294M Sales 2025 * 357M Capitalization 1.62B
Net income 2024 * 33M Net income 2025 * 62M EV / Sales 2024 * 3.55 x
Net cash position 2024 * 577M Net cash position 2025 * 714M EV / Sales 2025 * 2.54 x
P/E ratio 2024 *
48.7 x
P/E ratio 2025 *
29.1 x
Employees 408
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.71%
More Fundamentals * Assessed data
Dynamic Chart
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue MT
Transcript : Dynavax Technologies Corporation, Q4 2023 Earnings Call, Feb 22, 2024
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024 CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Goldman Sachs Initiates Dynavax Technologies at Neutral Rating With $20 Price Target MT
Transcript : Dynavax Technologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to NASDAQ Biotechnology Index CI
Dynavax Technologies Insider Sold Shares Worth $300,000, According to a Recent SEC Filing MT
Dynavax Technologies Insider Sold Shares Worth $282,400, According to a Recent SEC Filing MT
Transcript : Dynavax Technologies Corporation, Q3 2023 Earnings Call, Nov 02, 2023
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q3 Revenue $69.5M, vs. Street Est of $61.4M MT
Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023 CI
Dynavax Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
More news

Latest transcript on Dynavax Technologies Corporation

1 day+0.32%
1 week+2.56%
Current month-2.05%
1 month-4.46%
3 months-12.17%
6 months-14.35%
Current year-11.23%
More quotes
1 week
12.05
Extreme 12.05
12.64
1 month
11.65
Extreme 11.65
13.27
Current year
11.65
Extreme 11.65
15.01
1 year
9.48
Extreme 9.48
15.15
3 years
7.09
Extreme 7.09
21.39
5 years
1.80
Extreme 1.8
21.39
10 years
1.80
Extreme 1.8
32.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 04-12-31
Director of Finance/CFO 40 21-02-28
President 62 13-03-24
Members of the board TitleAgeSince
Director/Board Member 79 09-11-02
Director/Board Member 70 06-07-31
Director/Board Member 77 10-07-21
More insiders
Date Price Change Volume
24-03-28 12.36 -0.36% 36 611
24-03-27 12.41 +0.32% 829,944
24-03-26 12.37 -1.04% 1,066,249
24-03-25 12.5 +1.71% 1,013,333
24-03-22 12.29 +1.07% 1,006,700

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.41 USD
Average target price
24.67 USD
Spread / Average Target
+98.76%
Consensus
  1. Stock
  2. Equities
  3. Stock Dynavax Technologies Corporation - Nasdaq